Medikamentöse Therapie:
TNF-Blocker
TNF-Blocker Präparatewahl
Tocilizumab
Interleukin 6
Wirkmechanismus
Einsatz
Ausgangs- und Kontrolluntersuchungen
Kontraindikationen
Infusion
Unerwünschte Wirkungen
Laborabweichungen
Infusionsreaktionen
Kombinations- und Monotherapie
Fazit
Anhang JIA
Literatur
Leflunomid
Rituximab
Abatacept
NSAR
Opioid-Analgetika
Mycophenolsäure
Immunglobuline
Anakinra



Lokaltherapie:
Topika
Radiosynoviorthese



Therapie bei:
Impfungen
Schwangerschaft
Kinder- und Jugendrheuma
Sjögren-Syndrom
Pulmonaler Hypertonie
Raynaud-Syndrom
Lyme Borreliose



Sonstige Stellungnahmen



Literaturverzeichnis

 

 

  1. Sato K, Tsuchiya M, Saldanha J et al. Reshaping a human antibody to inhibit the inter-leukin 6-dependent tumor cell growth. Cancer Res 1993; 53(4):851-856.

  2. Nishimoto N, Kanakura Y, Aozasa K et al. Humanized anti-interleukin-6 receptor anti-body treatment of multicentric Castleman disease. Blood 2005; 106(8):2627-2632.

  3. Yokota S, Miyamae T, Imagawa T et al. Therapeutic efficacy of humanized recombi-nant anti-interleukin-6 receptor antibody in children with systemic-onset juvenile idio-pathic arthritis. Arthritis Rheum 2005; 52(3):818-825.

  4. Ito H, Takazoe M, Fukuda Y et al. A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease. Gastroenterology 2004; 126(4):989-996.

  5. Kishimoto T. The biology of interleukin-6. Blood 1989; 74(1):1-10.

  6. Kishimoto T. Interleukin-6: discovery of a pleiotropic cytokine. Arthritis Res Ther 2006; 8 Suppl 2:S2.

  7. Choy E. Inhibiting interleukin-6 in rheumatoid arthritis. Curr Rheumatol Rep 2008; 10(5):413-417.

  8. Kotake S, Sato K, Kim KJ et al. Interleukin-6 and soluble interleukin-6 receptors in the synovial fluids from rheumatoid arthritis patients are responsible for osteoclast-like cell formation. J Bone Miner Res 1996; 11(1):88-95.

  9. Uson J, Balsa A, Pascual-Salcedo D et al. Soluble interleukin 6 (IL-6) receptor and IL-6 levels in serum and synovial fluid of patients with different arthropathies. J Rheumatol 1997; 24(11):2069-2075.

  10. Guerne PA, Zuraw BL, Vaughan JH et al. Synovium as a source of interleukin 6 in vitro. Contribution to local and systemic manifestations of arthritis. J Clin Invest 1989; 83(2):585-592.

  11. Mihara M, Kasutani K, Okazaki M et al. Tocilizumab inhibits signal transduction mediated by both mIL-6R and sIL-6R, but not by the receptors of other members of IL-6 cytokine family. Int Immunopharmacol 2005; 5(12):1731-1740.

  12. Nishimoto N, Yoshizaki K, Maeda K et al. Toxicity, pharmacokinetics, and dose-finding study of repetitive treatment with the humanized anti-interleukin 6 receptor antibody MRA in rheumatoid arthritis. Phase I/II clinical study. J Rheumatol 2003; 30(7):1426-1435.

  13. Emery P, Keystone E, Tony HP et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis 2008; 67(11):1516-1523.

  14. Genovese MC, McKay JD, Nasonov EL et al. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthritis Rheum 2008; 58(10):2968-2980.

  15. Jones G, Sebba A, Gu J et al. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: The AMBITION study. Ann Rheum Dis 2009.

  16. Kremer JM, Fleischmann RM, Brzezicki P et al. Tocilizumab inhibits structural joint damage, improves physical function and and increases DAS28 remission rates in RA patients who respond inadequately to methotrexate: The LITHE study. EULAR 2009 2009; Kopenhagen(Vortrag OP 157).

  17. Rubbert-Roth A, Heinzl S. Tocilizumab bei rheumatoider Arthritis. Arzneimitteltherapie 2009; 10.

  18. Smolen JS, Beaulieu A, Rubbert-Roth A et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet 2008; 371(9617):987-997.

  19. Lipsky PE. Interleukin-6 and rheumatic diseases. Arthritis Res Ther 2006; 8 Suppl 2:S4.

  20. Maini RN, Taylor PC, Szechinski J et al. Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum 2006; 54(9):2817-2829.

  21. Keystone E, John A, Wong K. Benefit of continuing treatment beyond 12 weeks in pa-tients with rheumatoid arthritis treated with tocilizumab. 2009: P411/P412-acr.confex.com/acr/2009/webprogram/Paper11664.html and 11673.

  22. Dutch Rheumatology Society. Indication and treatment of rheumatoid arthritis with to-cilizumab (anti-IL-6 therapy). Position Paper 2009; 10:1-6.

  23. Koike R, Harigai M, Atsumi T et al. Japan College of Rheumatology 2009 guidelines for the use of tocilizumab, a humanized anti-interleukin-6 receptor monoclonal antibody, in rheumatoid arthritis. Mod Rheumatol 2009; 19(4):351-357.

  24. Kobayashi K, Okamoto Y, Inoue H et al. Leukoencephalopathy with cognitive impair-ment following tocilizumab for the treatment of rheumatoid arthritis (RA). Intern Med 2009; 48(15):1307-1309.

  25. Van Vollenhoven RF, Keystone E, Furie R et al. Gastrointestinal Safety in Patients with Rheumatoid Arthritis treated with Tocilizumab: Data From Roche Clinical trials. 2009: P1613-acr.confex.com/acr/2009/webprogram/Paper11711.html.

  26. De Benedetti F., Massa M, Robbioni P et al. Correlation of serum interleukin-6 levels with joint involvement and thrombocytosis in systemic juvenile rheumatoid arthritis. Arthritis Rheum 1991; 34(9):1158-1163.

  27. De Benedetti F., Martini A. Targeting the interleukin-6 receptor: a new treatment for systemic juvenile idiopathic arthritis? Arthritis Rheum 2005; 52(3):687-693.

  28. Woo P, Wilkinson N, Prieur AM et al. Open label phase II trial of single, ascending dos-es of MRA in Caucasian children with severe systemic juvenile idiopathic arthritis: proof of principle of the efficacy of IL-6 receptor blockade in this type of arthritis and demon-stration of prolonged clinical improvement. Arthritis Res Ther 2005; 7(6):R1281-R1288.

  29. Yokota S, Imagawa T, Mori M et al. Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial. Lancet 2008; 371(9617):998-1006.

  30. Manger B, Gaubitz M, Michels H, Kommission Pharmakotherapie der DGRh. Empfeh-lungen zur Therapie mit Interleukin-1-beta-blockierenden Wirkstoffen. Z Rheumatol 2009;68:766-771.



Therapie-Empfehlung Tocilizumab

 

Druckversion (PDF)